ArticleProceedings of the National Academy of Sciences of the United States of America2024
Design of universal Ebola virus vaccine candidates via immunofocusing.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Mapping the research landscape of antibody therapy for Ebola virus disease: a bibliometric analysis.Frontiers in immunology · 2026Pooled it
- Design of Epitope-Focused Vaccines via Epitope Cleavage.ACS central science · 2026Article
- Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses.Nature communications · 2026Article
- Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.PLoS pathogens · 2026Article
- Bundibugyo Virus Disease: Diagnostics and Medical Countermeasures for a Neglected Ebolavirus.Viruses · 2026Review
- Mapping the global evidence base of bundibugyo ebolavirus disease: a systematic scoping review of research gaps and preparedness priorities.BMC infectious diseases · 2026Article
- Article
- Oriented Multivalent Display Drives Consistent Serum Immunodominance to the Ebola Virus Glycoprotein.ACS central science · 2026Article
- Architects of folding, editors of immunity: the strategic use ofFrontiers in immunology · 2026Article
- Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification.Nature communications · 2025Article
- mRNA vaccine based on high-frequency prevalent antigens provides broad protection against influenza B virus.Molecular therapy. Nucleic acids · 2025Article
- Immunofocusing design of a fusion glycoprotein monomer vaccine for respiratory syncytial virus.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Design of Hyperglycosylated Zika Virus E Proteins that Focus Antibody Recognition on the Complex E Dimer Epitope.ACS chemical biology · 2025Article
- Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification.bioRxiv : the preprint server for biology · 2025Article
- A two-component cocktail of engineered DIII nanoparticles elicits broadly neutralizing antibody responses against dengue virus in mice.iScience · 2025Article
- Making Universal Vaccines and Antibodies Through Glycoengineering.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Glycan masking in immunogen design: computational and experimental methods.Frontiers in immunology · 2025Review
- Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines.International journal of molecular sciences · 2024Review
- Engineered protein subunit COVID19 vaccine is as immunogenic as nanoparticles in mouse and hamster models.Scientific reports · 2024Article
- Ferritin Vaccine Platform for Animal and Zoonotic Viruses.Vaccines · 2024Review
Corrections and comments
- Update of
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
The Ebola virus causes hemorrhagic fever in humans and poses a significant threat to global public health. Although two viral vector vaccines have been approved to prevent Ebola virus disease, they are distributed in the limited ring vaccination setting and only indicated for prevention of infection from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.